Premium
MiR‐205 suppresses tumor growth, invasion, and epithelial‐mesenchymal transition by targeting SEMA4C in hepatocellular carcinoma
Author(s) -
Lu Jiong,
Lin Yixin,
Li Fuyu,
Ye Hui,
Zhou Rongxing,
Jin Yanwen,
Li Bei,
Xiong Xianze,
Cheng Nansheng
Publication year - 2018
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fj.201800113r
Subject(s) - cancer research , ectopic expression , carcinogenesis , hepatocellular carcinoma , epithelial–mesenchymal transition , biology , microrna , cell growth , cell culture , apoptosis , metastasis , cancer , gene , biochemistry , genetics
Growing evidence indicates that microRNAs are involved in tumorigenesis and progression of hepa tocellular carcinoma (HCC). However, the functional mechanisms of miR‐205 in HCC remain largely unknown. Here, we demonstrate that miR‐205 expression was significantly down‐regulated in HCC tissues and cell lines and was correlated with metastatic pathologic features and shorter disease‐free and overall survival. Overexpression of miR‐205 dramatically inhibited HCC cell proliferation, apoptosis, migration, invasion, epithelial‐mesenchymal transition (EMT) in vitro, and tumor growth in vivo. We subsequently identified semaphorin 4C (SEMA4C) as a novel target of miR‐205. Furthermore, high expression levels of SEMA4C were frequently found in HCC tissues and were associated with poor prognosis. Ectopic expression of SEMA4C restored the suppressive effect of overex pressed miR‐205 on migration, invasion, and EMT. Taken together, our findings provide new insight into the critical role of miR‐205 in regulating tumor growth, invasion, and EMT of HCC, suggesting miR‐205 may serve as a promising therapeutic target and novel prognostic indicator for patients with HCC.—Lu, J., Lin, Y., Li, F., Ye, H., Zhou, R., Jin, Y., Li, B., Xiong, X., Cheng, N. MiR‐205 suppresses tumor growth, invasion, and epithelialmesenchymal transition by targeting SEMA4C in hepatocellular carcinoma. FASEB J. 32, 6123–6134 (2018). www.fasebj.org